The HPA Axis Explained: How Chronic Stress Depletes Your Body

HPA Axis and Chronic Stress are two terms that often appear together in wellness conversations, but the relationship between them is rarely explained well. When stress becomes a daily fixture rather than an occasional challenge, the body's primary stress-response system can shift from protective to destructive. Understanding how this happens is the first step toward reversing it.

What the HPA Axis Actually Does

The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress command center. It links the hypothalamus in the brain to the pituitary gland and the adrenal glands sitting atop the kidneys. This hormonal relay system evolved to handle acute threats: a predator, a physical injury, a sudden demand for alertness.

Here's the sequence. The hypothalamus releases corticotropin-releasing hormone (CRH), signaling the pituitary to secrete adrenocorticotropic hormone (ACTH). ACTH travels to the adrenal cortex and triggers the release of cortisol, the body's main glucocorticoid stress hormone. Cortisol raises blood glucose, sharpens focus, and suppresses non-essential functions like digestion and immune surveillance. In short bursts, this is adaptive. In chronic activation, it becomes costly.

The HPA axis also operates under negative feedback. Elevated cortisol should signal the hypothalamus and pituitary to dial back CRH and ACTH output. This feedback loop is what allows the system to return to baseline after a stressor passes. Chronic stress can blunt or dysregulate this feedback, leading to sustained cortisol elevation or, paradoxically, eventual cortisol depletion in some individuals.

The Evidence Base

Human research on HPA axis modulation by adaptogenic herbs has expanded meaningfully over the past decade. The strongest evidence comes from randomized, double-blind, placebo-controlled trials (RCTs) in adults with self-received stress or anxiety.

Chandrasekhar et al. (2012) conducted a 60-day RCT of a high-concentration full-spectrum ashwagandha root extract in 64 adults with chronic stress. Participants receiving the extract showed significant reductions in serum cortisol compared to placebo, alongside improvements on stress-assessment scales. The study was placebo-controlled and adequately powered for its primary endpoints.

Langade et al. (2019) extended this to insomnia and anxiety, testing ashwagandha root extract in a triple-blind, randomized, placebo-controlled study. The treatment group demonstrated improvements in sleep onset latency, sleep efficiency, and anxiety scores. The design strengthens the signal, though the sample was modest in size.

Pratte et al. (2014) published a systematic review of human trials on ashwagandha for anxiety, finding consistent trends toward reduced anxiety scores across five trials. The authors noted that all included studies were limited by small sample sizes and short durations, and called for larger, longer trials to confirm efficacy.

Studies on related outcomes — muscle recovery and cognitive function — provide mechanistic context but do not directly measure HPA axis activity. Wankhede et al. (2015) found that ashwagandha supplementation increased muscle strength and reduced exercise-induced muscle damage in healthy young men. Choudhary et al. (2017) reported improvements in executive function, sustained attention, and information processing speed in adults with mild cognitive impairment. Neither study measured cortisol directly, so claims about HPA axis effects here would be speculative.

Study	Design	Population	Duration	Primary Outcome	HPA-Related Finding
Chandrasekhar et al. (2012)	RCT, double-blind, placebo-controlled	64 adults with chronic stress	60 days	Serum cortisol, perceived stress	Significant cortisol reduction vs. placebo
Langade et al. (2019)	RCT, triple-blind, placebo-controlled	Adults with insomnia and anxiety	10 weeks	Sleep quality, anxiety scores	Improved sleep and anxiety; cortisol not measured
Pratte et al. (2014)	Systematic review	5 RCTs in anxious adults	Varied (6–12 weeks)	Anxiety symptom reduction	Consistent trend; authors note limited data
Wankhede et al. (2015)	RCT, double-blind, placebo-controlled	57 healthy young men	8 weeks	Muscle strength, recovery	No direct HPA measurement
Choudhary et al. (2017)	RCT, double-blind, placebo-controlled	50 adults with mild cognitive impairment	8 weeks	Cognitive function	No direct HPA measurement

The Mechanism

How might ashwagandha — specifically Withania somnifera root extracts — influence the HPA axis? The answer is not fully resolved, but several mechanisms have been proposed based on preclinical and limited human data.

Ashwagandha contains withanolides, steroidal lactones that appear to interact with GABA receptors and modulate signaling pathways involved in the stress response. Preclinical work suggests that withanolides may reduce cortisol secretion by dampening CRH-induced ACTH release at the pituitary level, or by enhancing glucocorticoid receptor sensitivity in the hippocampus, thereby restoring negative feedback efficiency. These mechanisms are supported primarily by animal and in vitro studies; direct human neuroendocrine confirmation is limited.

There is also evidence that ashwagandha reduces systemic markers of inflammation, including C-reactive protein and interleukin-6, which are themselves activators of the HPA axis. Lowering inflammatory tone may indirectly reduce the drive on the hypothalamus to initiate the cortisol cascade. This anti-inflammatory pathway is better characterized than direct HPA receptor interactions, but the clinical relevance to stress resilience remains an active area of investigation.

For readers interested in how cortisol interacts with other systems under chronic stress, our article on how stress depletes the body through the cortisol-magnesium-NAD+ vicious cycle covers the downstream metabolic consequences in more detail.

What Chronic HPA Dysregulation Looks Like

HPA axis dysfunction does not present identically in everyone. In some individuals, chronic stress produces hypercortisolism: elevated baseline cortisol, flattened diurnal rhythm (the normal morning peak and evening trough disappear), and exaggerated response to minor stressors. This state is associated with visceral fat accumulation, impaired glucose tolerance, sleep fragmentation, and memory deficits.

In others, particularly after prolonged or severe stress, the axis may shift toward hypocortisolism: low baseline cortisol, blunted ACTH response, and fatigue-dominated symptom profiles. This pattern is observed in some cases of burnout, chronic fatigue syndrome, and post-traumatic stress disorder. The transition from hyper- to hypocortisolism is not well understood and likely involves glucocorticoid receptor downregulation and neuroinflammatory changes.

Most healthy adults fall somewhere between these extremes, with subtle shifts in cortisol rhythm that may not meet clinical thresholds but still affect energy, sleep, and recovery. The evidence that adaptogenic herbs can restore normal rhythm in these subclinical cases is promising but early.

Who Benefits Most

The strongest human evidence for ashwagandha's stress-modulating effects comes from adults with self-reported chronic stress or mild-to-moderate anxiety. Chandrasekhar et al. (2012) and Langade et al. (2019) both recruited from this population and found measurable improvements in cortisol and symptom scores.

Athletes and physically active individuals may also benefit, though the mechanism shifts. Wankhede et al. (2015) demonstrated improved muscle strength and recovery in resistance-trained men. Whether this operates through HPA axis modulation, reduced inflammation, or direct muscle protein effects is unclear. The study did not measure cortisol, so HPA-specific claims here are unsupported.

Adults with mild cognitive impairment showed cognitive benefits in Choudhary et al. (2017), but this was a small, short trial. There is no direct evidence that ashwagandha improves HPA axis function in cognitively impaired populations specifically.

Importantly, none of the cited studies included pregnant or breastfeeding women, children, or individuals with diagnosed psychiatric disorders. Safety and efficacy in these groups are unknown. The Pratte et al. (2014) review explicitly noted that all available trials were limited by small samples and short follow-up, so generalization should be cautious.

Those interested in the specifics of how ashwagandha interacts with cortisol signaling can read our deeper dive on the ashwagandha-cortisol mechanism.

Forms, Dosing, and Practical Considerations

Not all ashwagandha preparations are equivalent. The cited RCTs used standardized root extracts with defined withanolide content, typically in the range of 5% withanolides by weight. Chandrasekhar et al. (2012) used 300 mg twice daily of a high-concentration full-spectrum extract. Langade et al. (2019) used 300 mg twice daily of a root extract standardized to a similar withanolide concentration.

Whole-root powder, unstandardized extracts, and leaf-only preparations have not been tested in the same rigorous designs. The withanolide profile differs across plant parts, and leaf extracts may contain higher levels of withaferin A, a compound with cytotoxic properties in cell studies whose human relevance is uncertain. For readers prioritizing the evidence base, root extracts standardized to withanolides and dosed at 600 mg/day in divided doses align most closely with the published trials.

Timing matters for HPA axis support. Because cortisol follows a circadian rhythm — peaking within 30–60 minutes of waking and declining through the evening — some clinicians recommend morning dosing to avoid interfering with the natural evening nadir. However, the RCTs cited here did not specify timing restrictions, and Langade et al. (2019) actually found sleep benefits, suggesting evening dosing may also be appropriate depending on the target outcome.

For those evaluating different supplement formats, Bio:sudo KSM-66 Reishi Restore provides a full-spectrum ashwagandha root extract combined with reishi mushroom. The KSM-66 extraction process is designed to preserve the natural ratio of withanolides found in the root, which matches the extract type used in several of the cited clinical trials.

Readers should also be aware that cortisol claims in supplement marketing often oversimplify a complex rhythm. Our guide on cortisol rhythm basics explains how to evaluate these claims critically.

What the Evidence Does Not Show

It is worth being explicit about the limits of the current evidence. No published RCT has demonstrated that ashwagandha cures HPA axis dysfunction, adrenal fatigue, or any diagnosed endocrine disorder. The term "adrenal fatigue" itself is not recognized by mainstream endocrinology and lacks consistent diagnostic criteria.

The cortisol reductions reported by Chandrasekhar et al. (2012) were statistically significant but modest in absolute terms — roughly 20–30% from baseline. Whether this magnitude of change translates to clinically meaningful improvements in metabolism, immunity, or longevity is unknown. Long-term trials beyond 12 weeks are absent.

There is also no direct evidence that ashwagandha prevents stress-related disease. The trials measure intermediate endpoints — cortisol levels, anxiety scores, sleep quality — not hard outcomes like cardiovascular events, diabetes incidence, or mortality. These limitations are standard for nutraceutical research but should temper expectations.

Practical Takeaways

• Chronic stress can dysregulate the HPA axis through impaired negative feedback, leading to either sustained cortisol elevation or eventual depletion depending on duration and individual factors.
• The best human evidence for ashwagandha's stress-modulating effects comes from RCTs in adults with chronic stress or mild anxiety, with cortisol reductions observed at 600 mg/day of standardized root extract.
• Choose root extracts standardized to withanolides (typically 5%) rather than unstandardized powders or leaf-only products, as these match the forms tested in rigorous trials.
• Ashwagandha is not a replacement for stress management fundamentals: sleep hygiene, physical activity, social connection, and, when indicated, professional mental health support.
• Do not expect dramatic or immediate results. The cited trials ran 8–10 weeks before measuring outcomes. Consistency matters more than dose escalation.
• If you are pregnant, breastfeeding, taking thyroid medication, sedatives, or immunosuppressants, consult a clinician before using ashwagandha. The cited trials excluded these populations.

Bottom Line

The HPA axis is a finely tuned stress-response system that suffers under chronic activation. A small but growing body of RCT evidence, led by Chandrasekhar et al. (2012) and supported by Langade et al. (2019) and Pratte et al. (2014), suggests that standardized ashwagandha root extract can modestly reduce cortisol and improve stress-related symptoms in healthy adults. The mechanism likely involves modulation of GABA signaling, glucocorticoid receptor sensitivity, and inflammatory tone, though human confirmation remains incomplete. It is a reasonable adjunct for stressed adults — not a standalone fix, and not a substitute for addressing the root causes of chronic stress.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian Journal of Psychological Medicine. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." Journal of the International Society of Sports Nutrition. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving memory and cognitive functions." Journal of Dietary Supplements. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." Journal of Alternative and Complementary Medicine. 2014;20(12):901–908. [Source]

---

---